ARQT

23.63

1.95% -0.47

Dopo l'orario di chiusura: 23.22 -0.41 -1.74%

Arcutis Biotherapeutics Inc (ARQT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARQT Giù? Forum Previsione

Precedente Chiudi:

$24.10

Aprire:

$23.4

Volume 24 ore:

1.09M

Relative Volume:

0.77

Capitalizzazione di mercato:

$2.93B

Reddito:

$376.07M

Utile/perdita netta:

$-16.14M

Rapporto P/E:

-168.91

EPS:

-0.1399

Flusso di cassa netto:

$-16.31M

1 W Prestazione:

+5.59%

1M Prestazione:

-4.56%

6M Prestazione:

+11.20%

1 anno Prestazione:

+42.35%

Intervallo 1D:

$23.24

$24.08

Intervallo di 1 settimana:

$21.12

$24.52

Portata 52W:

$11.86

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Nome

Arcutis Biotherapeutics Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

805-418-5006

Indirizzo

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Dipendente

354

Cinguettio

@ArcutisBio

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARQT Arcutis Biotherapeutics Inc	23.63	2.93B	376.07M	-16.14M	-16.31M	-0.1399
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-25	Iniziato	Goldman	Neutral
2024-12-30	Iniziato	H.C. Wainwright	Buy
2024-08-28	Iniziato	Jefferies	Buy
2024-01-03	Aggiornamento	Mizuho	Neutral → Buy
2023-10-26	Downgrade	Mizuho	Buy → Neutral
2023-10-13	Downgrade	Goldman	Buy → Neutral
2022-09-07	Iniziato	Needham	Buy
2022-03-17	Iniziato	Goldman	Buy
2021-06-30	Iniziato	Mizuho	Buy
2021-05-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Aggiornamento	Goldman	Neutral → Buy
2020-10-08	Iniziato	Truist	Buy
2020-02-25	Iniziato	Cantor Fitzgerald	Overweight
2020-02-25	Iniziato	Cowen	Outperform
2020-02-25	Iniziato	Goldman	Neutral
2020-02-25	Iniziato	Guggenheim	Buy

Mostra tutto

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

Apr 04, 2026

Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Apr 04, 2026

Apr 03, 2026

Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus

Apr 03, 2026

Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat

Apr 03, 2026

Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - Stock Titan

Apr 01, 2026

Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Moomoo

Apr 01, 2026

Mar 31, 2026

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget

Mar 31, 2026

Arcutis executives join Needham virtual health conference April 14 - Stock Titan

Mar 31, 2026

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 8.7%Here's Why - MarketBeat

Mar 31, 2026

Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 31, 2026

Mar 30, 2026

Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 30, 2026

Mar 29, 2026

Aug Big Picture: What are the future prospects of Arcutis Biotherapeutics Inc2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn

Mar 29, 2026

Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN

Mar 29, 2026

Mar 28, 2026

Arcutis presents trial data on roflumilast cream for infants By Investing.com - Investing.com Canada

Mar 28, 2026

Arcutis presents trial data on roflumilast cream for infants - Investing.com

Mar 28, 2026

Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis - Quiver Quantitative

Mar 28, 2026

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times

Mar 28, 2026

Nearly half of infants saw eczema itch ease in 10 minutes - Stock Titan

Mar 28, 2026

Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN

Mar 28, 2026

Mar 27, 2026

Nordea Investment Management AB Acquires New Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 27, 2026

Mar 26, 2026

[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan

Mar 26, 2026

Silverleafe Capital Partners LLC Increases Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Mar 26, 2026

Mar 23, 2026

Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily

Mar 23, 2026

Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance

Mar 23, 2026

Mar 19, 2026

A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness - simplywall.st

Mar 19, 2026

Mar 18, 2026

Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey

Mar 18, 2026

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget

Mar 18, 2026

Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus

Mar 18, 2026

New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan

Mar 18, 2026

Mar 17, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 17, 2026